Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02494570 · OUTCOME

Progression-free Survival (Median)

A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComa · Source last updated 2023-04-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
from start of treatment to first documented disease progression, through study completion (up to 72 months)

What was measured

The time from the first dose date to the first observation of a disease progression or death due to any cause.

Analysis population: Efficacy Evaluable Patient Population

Groups in this outcome

Experimental: Nab-Sirolimus

Patients with malignant PEComa were treated with 100 mg/m2 nab-sirolimus (30 mins IV infusion) on Days 1 and 8 in a 21-day cycle.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Experimental: Nab-Sirolimus31

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Experimental: Nab-Sirolimus10.6Not reported5.553.1Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        5.5
        upper Limit
        53.1
        value
        10.6
denoms
  1. counts
    1. group Id
      OG000
      value
      31
    units
    Participants
description
The time from the first dose date to the first observation of a disease progression or death due to any cause.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients with malignant PEComa were treated with 100 mg/m2 nab-sirolimus (30 mins IV infusion) on Days 1 and 8 in a 21-day cycle.
    id
    OG000
    title
    Experimental: Nab-Sirolimus
param Type
MEDIAN
population Description
Efficacy Evaluable Patient Population
reporting Status
POSTED
time Frame
from start of treatment to first documented disease progression, through study completion (up to 72 months)
title
Progression-free Survival (Median)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice